Related Experiment Video
Updated: Jul 25, 2025
09:53
In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
Published on: July 27, 2010
16.0K
Cysteinyl-leukotrienes promote cutaneous Leishmaniasis control
Letícia Paula Trajano Noronha1, Monique Daiane Andrade Martins1, Archimedes Barbosa Castro-Junior1
1Laboratory of Immunophysiology, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Frontiers in Cellular and Infection Microbiology
|June 28, 2023
Summary
Cysteinyl leukotrienes (Cys-LTs) effectively control Leishmania amazonensis infection in mouse models. This study reveals Cys-LTs as potential therapeutic targets for cutaneous leishmaniasis (CL).
Area of Science:
- Immunology
- Parasitology
- Pharmacology
Background:
- Leishmaniasis is a neglected tropical disease with limited treatment options.
- Cutaneous leishmaniasis (CL) is the most common form, causing significant global health burden.
- Leukotrienes, including cysteinyl leukotrienes (Cys-LTs), are inflammatory mediators with unknown roles in leishmaniasis.
Purpose of the Study:
- To investigate the role of Cys-LTs in controlling Leishmania amazonensis infection.
- To evaluate the therapeutic potential of Cys-LTs for cutaneous leishmaniasis.
Main Methods:
- In vitro studies using peritoneal macrophages from susceptible (BALB/c) and resistant (C57BL/6) mice.
- In vivo studies using a mouse model of CL (L. amazonensis-infected C57BL/6 mice).
- Assessment of infection index, lesion size, and parasite load; investigation of the P2X7 receptor's role.
Main Results:
- Cys-LTs significantly reduced L. amazonensis infection in macrophages in vitro.
- Intralesional Cys-LT treatment decreased lesion size and parasite burden in vivo.
- The anti-leishmanial effect of Cys-LTs was dependent on the purinergic P2X7 receptor.
Conclusions:
- Cys-LTs play a crucial role in controlling Leishmania amazonensis infection.
- Cys-LTs demonstrate therapeutic potential for treating cutaneous leishmaniasis.
- Targeting Cys-LTs and the P2X7 receptor pathway may offer new treatment strategies for CL.
More Related Videos
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
371
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
371
01:24T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K